Market capitalization | $1.05b |
Enterprise Value | $1.36b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 152.08 |
EV/Sales (TTM) EV/Sales | 3.61 |
P/S ratio (TTM) P/S ratio | 2.79 |
P/B ratio (TTM) P/B ratio | 3.56 |
Revenue growth (TTM) Revenue growth | 14.68% |
Revenue (TTM) Revenue | $376.97m |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
5 Analysts have issued a CryoLife forecast:
5 Analysts have issued a CryoLife forecast:
Jun '24 |
+/-
%
|
||
Revenue | 377 377 |
15%
15%
|
|
Gross Profit | 228 228 |
16%
16%
|
|
EBITDA | 84 84 |
161%
161%
|
EBIT (Operating Income) EBIT | 61 61 |
527%
527%
|
Net Profit | -8.33 -8.33 |
71%
71%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
CryoLife, Inc. engages in the manufacture, process and distribution of medical devices. It operates through the following segments: Medical Devices and Preservation Services. The Medical Devices segment includes revenues from sales of BioGlue; JOTEC products, On-X products, CardioGenesis cardiac laser therapy, PerClot and PhotoFix. The Preservation Services segment focuses on external services revenues from the preservation of cardiac and vascular tissues. The company was founded on January 19, 1984 and is headquartered in Kennesaw, GA.
Head office | United States |
CEO | James Mackin |
Employees | 1,500 |
Founded | 1984 |
Website | www.artivion.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.